Literature DB >> 24349909

Label-free analysis of o-glycosylation site-occupancy based on the signal intensity of glycopeptide/peptide ions.

Yoshinao Wada1.   

Abstract

Mucin-type O-glycosylation is a major posttranslational modification of proteins. The level of O-glycosylation at a site could be useful in terms of evaluating various disease conditions. To address the feasibility of measuring O-glycosylation levels based on the glycopeptide ion intensity in a mass spectrum, apolipoprotein CIII (apoC3), a protein that contains a single core-1 O-glycan Gal-GalNAc disaccharide was analyzed by matrix-assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS). The intensity of protonated ions for an equimolar mixture of desialylated and deglycosylated apoC3s were the same in linear TOF measurements. No substantial in-source decay, including the cleavage of the protein-sugar linkage was observed. The glycopeptide derived from apoC3 and the unglycosylated counterpart, when analyzed by MALDI reflectron TOF MS indicated that post-source decay was minimal. These collective findings demonstrate the feasibility of label-free quantitation of O-glycan occupancy by MS when the glycans are small and neutral. This method provides a tool for use in glycoproteomics as a complement of our previous report (DOI: 10.1021/pr900913k) for calculating the saccharide composition of O-glycans.

Entities:  

Keywords:  O-glycan; apolipoprotein CIII; in-source decay; label-free quantitation; matrix-assisted laser desorption/ionization

Year:  2012        PMID: 24349909      PMCID: PMC3775828          DOI: 10.5702/massspectrometry.A0008

Source DB:  PubMed          Journal:  Mass Spectrom (Tokyo)        ISSN: 2186-5116


  19 in total

1.  Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study.

Authors:  Yoshinao Wada; Parastoo Azadi; Catherine E Costello; Anne Dell; Raymond A Dwek; Hildegard Geyer; Rudolf Geyer; Kazuaki Kakehi; Niclas G Karlsson; Koichi Kato; Nana Kawasaki; Kay-Hooi Khoo; Soohyun Kim; Akihiro Kondo; Erika Lattova; Yehia Mechref; Eiji Miyoshi; Kazuyuki Nakamura; Hisashi Narimatsu; Milos V Novotny; Nicolle H Packer; Hélène Perreault; Jasna Peter-Katalinic; Gottfried Pohlentz; Vernon N Reinhold; Pauline M Rudd; Akemi Suzuki; Naoyuki Taniguchi
Journal:  Glycobiology       Date:  2007-01-12       Impact factor: 4.313

2.  Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient.

Authors:  Yoshinao Wada; Machiko Kadoya; Nobuhiko Okamoto
Journal:  Glycobiology       Date:  2012-05-18       Impact factor: 4.313

3.  Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2.

Authors:  Uwe Kornak; Ellen Reynders; Aikaterini Dimopoulou; Jeroen van Reeuwijk; Bjoern Fischer; Anna Rajab; Birgit Budde; Peter Nürnberg; Francois Foulquier; Dirk Lefeber; Zsolt Urban; Stephanie Gruenewald; Wim Annaert; Han G Brunner; Hans van Bokhoven; Ron Wevers; Eva Morava; Gert Matthijs; Lionel Van Maldergem; Stefan Mundlos
Journal:  Nat Genet       Date:  2007-12-23       Impact factor: 38.330

4.  Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis.

Authors:  Suzan Wopereis; Stephanie Grünewald; Eva Morava; Johannes M Penzien; Paz Briones; M Teresa García-Silva; Pierre N M Demacker; Karin M L C Huijben; Ron A Wevers
Journal:  Clin Chem       Date:  2003-11       Impact factor: 8.327

5.  Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin secretion and cell survival.

Authors:  Vishwanathan Hucthagowder; Eva Morava; Uwe Kornak; Dirk J Lefeber; Björn Fischer; Aikaterini Dimopoulou; Annika Aldinger; Jiwon Choi; Elaine C Davis; Dianne N Abuelo; Maciej Adamowicz; Jumana Al-Aama; Lina Basel-Vanagaite; Bridget Fernandez; Marie T Greally; Gabriele Gillessen-Kaesbach; Hulya Kayserili; Emmanuelle Lemyre; Mustafa Tekin; Seval Türkmen; Beyhan Tuysuz; Berrin Yüksel-Konuk; Stefan Mundlos; Lionel Van Maldergem; Ron A Wevers; Zsolt Urban
Journal:  Hum Mol Genet       Date:  2009-03-25       Impact factor: 6.150

Review 6.  Mass spectrometry for congenital disorders of glycosylation, CDG.

Authors:  Yoshinao Wada
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-03-06       Impact factor: 3.205

Review 7.  Congenital Disorders of Glycosylation: CDG-I, CDG-II, and beyond.

Authors:  Hudson H Freeze
Journal:  Curr Mol Med       Date:  2007-06       Impact factor: 2.222

Review 8.  Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation.

Authors:  James N Arnold; Radka Saldova; Umi M Abd Hamid; Pauline M Rudd
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

9.  A method for determination of N-glycosylation sites in glycoproteins by collision-induced dissociation analysis in fast atom bombardment mass spectrometry: identification of the positions of carbohydrate-linked asparagine in recombinant alpha-amylase by treatment with peptide-N-glycosidase F in 18O-labeled water.

Authors:  J Gonzalez; T Takao; H Hori; V Besada; R Rodriguez; G Padron; Y Shimonishi
Journal:  Anal Biochem       Date:  1992-08-15       Impact factor: 3.365

10.  Quantitation of saccharide compositions of O-glycans by mass spectrometry of glycopeptides and its application to rheumatoid arthritis.

Authors:  Yoshinao Wada; Michiko Tajiri; Shiro Ohshima
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

View more
  2 in total

Review 1.  N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.

Authors:  Lucia F Zacchi; Benjamin L Schulz
Journal:  Glycoconj J       Date:  2015-12-05       Impact factor: 2.916

Review 2.  Quantitative mass spectrometric analysis of glycoproteins combined with enrichment methods.

Authors:  Yeong Hee Ahn; Jin Young Kim; Jong Shin Yoo
Journal:  Mass Spectrom Rev       Date:  2014-06-02       Impact factor: 10.946

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.